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Accepted 28 March 2016Horses affected with gastrointestinal conditions such as colic or colitis are at substantial risk for translocation of
bacterial components such as lipopolysaccharide (LPS, endotoxin) from the gastrointestinal tract into circulation
resulting in systemic inﬂammation and subsequent morbidity andmortality. Therefore, there is a need for effec-
tive preventive and treatment strategies aimed at minimizing the host's inﬂammatory reaction to these
pathogen-associated molecular patterns (PAMPs) from gastrointestinal disease. Resveratrol (RES, trans-3,5,4′-
trihydroxystilbene) is a phytoalexin commonly found in fruits and beverages, including redwine. Health beneﬁts
associated with the consumption of red wine have been attributed to RES. Resveratrol has been signiﬁcantly
shown to exert a powerful anti-inﬂammatory effect in laboratory animals subjected to experimental
endotoxemia/sepsis. Therefore, the objective of this study was to determine in vitrowhether RES had an inhibi-
tory effect on the production of tumor necrosis factor (TNF) in cultivated whole blood (Cwb) following stimula-
tion by PAMPs. We hypothesized that RES would inhibit TNF production in Cwb following stimulation by LPS or
lipoteichoic acid (LTA). Production of TNF bioactivity in Cwbwasmeasured in thepresence of phosphate buffered
saline (control), ethanol (solvent control), dexamethasone (anti-inﬂammatory control), LPS, LTA, and three dif-
ferent concentrations of RES. Both LPS and LTA stimulated TNF production, and addition of dexamethasone was
inhibitory to this effect. An anti-inﬂammatory effect for RESwas not demonstrated under the current experimen-
tal conditions. Further studies are required to characterize the effect of RES on the equine innate immune system
during systemic inﬂammation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Gastrointestinal diseaseResveratrol (RES; trans-3.4′,5-trihydroxystilbene) is a small, non-
ﬂavonoid, polyphenolic phytoalexin compound found in wine (grape
skin), fruits, and certain plants that exhibits cell growth-modulatory
and anti-carcinogenic effects (Manna et al., 2000; Miller and Rice-
Evans, 1995). More recently, RES has been shown to exert an anti-
inﬂammatory effect in laboratory animals subjected to experimental
endotoxemia/sepsis (Sebai et al., 2008; Sebai et al., 2009). The mecha-
nisms of action of RES appear to be pleiotropic and are presently being
subjected to considerable investigative effort. Of relevance to systemic
inﬂammation resulting from infection, RES inhibits LPS- and TNF-
induced activation of nuclear factor-kappa-beta (NF-κB) (Gonzales
and Orlando, 2008; Manna et al. 2000). Although the speciﬁc mecha-
nism is incompletely understood (Adib-Conquy and Cavaillon, 2007),
recent studies have shown that RES increases silent information regula-
tor T1 (SIRT1) protein in cells (Baarsch et al., 1991; Barton and Collatos,
1999). SIRT1 suppresses pro-inﬂammatory cytokine production by).
. This is an open access article underreducing NF-κB subunit RelA/p65 acetylation, which is SIRT1 depen-
dent. RES inhibits TNF-α-induced inﬂammation via SIRT1 (Adib-
Conquy and Cavaillon, 2007 and Olholm et al., 2010).
Inﬂammation secondary to bacterial infection or translocation rep-
resents one of the most common causes of morbidity and mortality in
the horse (Moore andVandenplas, 2014). Bacteria initiate inﬂammation
through binding of pattern recognition receptors such as TLR-4 andTLR-
2. This binding results in activation of myeloid differentiation primary
response gene 88 (MyD88) and Toll/Interleukin-1 receptor-domain-
containing adapter-inducing interferon-β (TRIF) signaling pathways
(Figueiredo et al., 2009). Both of these signaling pathways promote ac-
tivation of NF-κB and its translocation into thenucleus, enabling binding
to speciﬁc sequences of DNA and resulting in gene transcription (TNF
expression) (Figueiredo et al., 2009). Stimulated production of TNF con-
tributes to the development of systemic inﬂammation and, if left unim-
peded, may result in multiple organ dysfunction (MOD; multiple organ
failure syndrome, MOFS) and death.
Anecdotally, RES is recommended as an anti-inﬂammatory dietary
supplement for horses and is purported to down-regulate pro-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. TNF production due to stimuli. Comparison of mean ± SD supernatant TNF
bioactivity from equine whole blood after treatment with phosphate buffered saline
(PBS; control), ethanol (EtOH; solvent control), dexamethasone (DEX; anti-
inﬂammatory control), resveratrol 0.23 mcg/ml (RES-L), resveratrol 2.28 mcg/ml (RES-
M) or resveratrol 22.80 mcg/ml (RES-H) and stimulation with phosphate buffered saline
(PBS; control), lipopolysaccharide (LPS), or lipoteichoic acid (LTA). a,bLPS and LTA
stimulation resulted in signiﬁcantly more supernatant TNF bioactivity overall compared
to PBS. cWhole blood incubated with DEX produced signiﬁcantly less TNF after LPS and
LTA stimulation compared to the other treatments except RES-L after LTA stimulation.
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concerning the impact of RES on immune function of primary equine
leukocytes is limited to a single study (Kohnen et al., 2007) in which
RES was shown to exert an enzyme inhibitory effect on neutrophil
myeloperoxidase (MPO), but cytokine production was not evaluated.
Other studies have shown that RES is also inhibitory to cellular produc-
tion of MPO (Chang et al., 2013).
Dietary RES supplementation to horses is currently commercially
available and marketed as an anti-inﬂammatory ‘nutraceutical’, despite
lack of evidence for efﬁcacy. Thus, we elected to evaluate whether RES
blunted pathogen-associated molecular pattern (PAMP)-induced TNF
production from equine whole blood using a whole blood culture
system. The employment of ex vivo cultivated whole blood (Cwb)
for purposes of determining leukocyte cytokine production capacity
is a method for evaluating leukocyte responses to different PAMP
stimuli in vitro (DeClue et al., 2012; Figueiredo et al., 2008). This
method has been employed extensively for investigation of innate
inﬂammatory responses in people and has been recently developed
for use in horses (DeClue et al., 2012). We hypothesized that
PAMP-stimulated TNF production by Cwb leukocytes would be
inhibited by inclusion of RES.
Heparinized whole blood was collected from the jugular vein of 10
adult Quarter Horses (8 mares and 2 stallions) judged to be healthy
based on physical examination and hematology. The mean age of the
horses was 12.9 years (median, 13.5 years; range, 2–22 years). None
of the horses exhibited disease or received medications in the previous
fourweeks. Animal usewas approved by theUniversity ofMissouri's In-
stitutional Animal Care and Use Committee.
Resveratrol (Sigma-Aldrich) was solubilized in ethanol. Final exper-
imental concentrations of 10−4 (22.8 μg/ml; RES-H), 10−5 (2.28 μg/ml;
RES-M), and 10−6 M (0.228 μg/ml; RES-L) were utilized.
Blood was processed within 2 h of collection (DeClue et al., 2012).
Brieﬂy,whole bloodwas diluted 1:2withmodiﬁedRoswell ParkMemo-
rial Institute medium (RPMI, Invitrogen) with penicillin/streptomycin
(Invitrogen) and L-glutamine (Invitrogen), and then 900 μl were
added to individual wells in 12-well plates. Either RES-H, RES-M, RES-
L, dexamethasone 100 μg/ml (anti-inﬂammatory control; APP Pharma-
ceuticals), ethanol (solvent control; Sigma-Aldrich), or phosphate buff-
ered saline (PBS, negative control) at a volume of 50 μl was added to
respective wells as treatments. Samples were thoroughly mixed imme-
diately and at 1 h following the initiation of incubation. Lipopolysaccha-
ride (LPS; Escherichia coli 0127:B8; Sigma-Aldrich) 100 ng/ml,
lipoteichoic acid (LTA; Streptococcus faecalis; Sigma-Aldrich)
1000 ng/ml, or PBS were added to respective wells as stimulants. Plates
were incubated at 37 °C, in 5% CO2 for 24 h. Then the samples were cen-
trifuged (300 xg for 6 min) and supernatants were collected and stored
(−80 °C) until analysis.
Supernatant TNF activity was evaluated in triplicate using a cytotox-
icity bioassay (Baarsch et al., 1991; DeClue et al., 2012). Brieﬂy, murine
ﬁbroblasts (L929)were cultured on 96-well plates for 12 h, and then the
(supernatant) samples were added. After a 20 h incubation with mini-
mum essential medium (MEM; Invitrogen) plus horse serum and acti-
nomycin D (Sigma-Aldrich), 3-[4.5-dimethylthiazol-2-yl]-2,5,-di-
phenyl tetrazolium bromide (Sigma-Aldrich) colorimetric assays were
used to quantify the number of live cells per well. Absorption was mea-
sured at 570 nm and optical density of test wells was compared to that
of wells with known concentrations of recombinant equine TNF (R&D
Systems) for quantiﬁcation. The lower limit of detection for this assay
is 0.5 ng/ml.
Statistical analysiswas performed using commercially available soft-
ware (SigmaStat, Systat Software Inc.). Kolmogorov-Smirnov's test was
used to determine whether data were normally distributed. Data that
were not normally distributed were transformed using the natural log
function. Data were compared using a repeated-measures analysis of
variance with post-hoc Fisher least signiﬁcant difference test with
p b 0.05 considered statistically signiﬁcant.LPS (100 ng/ml) and LTA (1000 ng/ml) stimulated TNF bioactivity
compared to un-stimulated (PBS) controls (Fig. 1). Inclusion of dexa-
methasone during the incubation of whole blood with both LPS and
LTA decreased the production of TNF bioactivity. Inclusion of RES in in-
cubation media failed to inhibit LPS- and LTA-stimulated increases in
TNF bioactivity.
As anticipated based on results of earlier work (DeClue et al., 2012),
both LPS- and LTA-stimulation resulted in signiﬁcantly increased TNF
production compared to un-stimulated (PBS) controls. Dexamethasone
was included as an anti-inﬂammatory control. As expected, inclusion of
dexamethasone in themedia signiﬁcantly inhibited TNF production fol-
lowing LPS and LTA stimulation compared to the other treatments ex-
cept RES-L after LTA stimulation. The concentrations of RES employed
were based on a previous study (Kohnen et al., 2007) in which RES
exerted a myeloperoxidase inhibiting effect on equine neutrophils
in vitro. However, RES failed to signiﬁcantly inhibit PAMP-induced TNF
production at all three tested concentrations. Many effects induced by
RES are dependent on the dose (Guerrero et al., 2009). It is important
to note that results of multiple investigations regarding the optimal
dose for RES during both in vitro and in vivo studies have failed to estab-
lish agreement and concordance (Smoliga et al., 2011).
It has been suggested that RES blocks the secretion of TNF through
inhibition of NF-κB (Foti Cuzzola et al., 2011; Kim et al., 2011; Palmieri
et al., 2011; Zang et al., 2011) and down-regulation of the expression
of pro-inﬂammatorymediators (Chang et al., 2011). Themode of action
of inhibition of NF-κB may be important in the context of equine
endotoxemia because bacterial LPS activates the innate immune system
leading to TNF secretion through the NF-κB pathway (Werners et al.,
2005). However, in another recent study, a single oral administration
of 5 g of RES to healthy adult human beings increased the circulating
plasma concentration of TNF-α and enhanced cytokine responses to
PAMPs by peripheral blood mononuclear cells (PBMC) and isolated
monocytes in vitro (Gualdoni et al., 2014). In that study, RES treatment
of human PBMC skewed cytokine release towards a pro-inﬂammatory
state following TLR-4 stimulation. Also, RES was shown to enhance
TNF-α production through activation of the alternative NF-κB pathway.
There are limitations to our project that may be addressed with fur-
ther studies, such as testing the effect of RES on other cytokines includ-
ing interleukin-1β and interleukin-6. Different concentrations of RES
may be utilized because the lack of effect in the present paper could
99L.M. Martin et al. / Research in Veterinary Science 106 (2016) 97–99simply be a concentration-dependent effect. Although the RES concen-
trations used in this study were based on previously published work
(Kohnen et al., 2007), results of that investigation cannot be directly
compared to results of this study because the methods were different.
Our investigation employed in vitro whole blood bioassay (Cwb) to de-
termine whether RES could inhibit TNF production, as detected in the
supernatant. Whole blood culture was utilized to allow all constituents
of blood to be present during PAMP-stimulated inﬂammatory response,
therefore, more closely mimicking the response in vivo. In contrast,
Kohnen et al. (2007) examined isolated polymorphonuclear leukocytes
(PMN) cultivated in PBS. In that study, activity of isolated equine PMN
myeloperoxidase was inhibited by RES at the same concentrations
used in this study. Moreover, in this study, resting and stimulated TNF
production could have resulted from other cells in blood.
The results indicate RES, at the tested concentrations, had no signif-
icant effect on LPS- or LTA-stimulated TNF production in an in vitro
whole blood bioassay. Further studies are required to characterize effect
of RES on the equine innate immune system during systemic
inﬂammation.
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